BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Coleman PJ, Schreier JD, Cox CD, Breslin MJ, Whitman DB, Bogusky MJ, Mcgaughey GB, Bednar RA, Lemaire W, Doran SM, Fox SV, Garson SL, Gotter AL, Harrell CM, Reiss DR, Cabalu TD, Cui D, Prueksaritanont T, Stevens J, Tannenbaum PL, Ball RG, Stellabott J, Young SD, Hartman GD, Winrow CJ, Renger JJ. Discovery of [(2 R ,5 R )-5-{[(5-Fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): A Dual Orexin Receptor Antagonist with Potent Sleep-Promoting Properties. ChemMedChem 2012;7:415-24. [DOI: 10.1002/cmdc.201200025] [Cited by in Crossref: 82] [Cited by in F6Publishing: 79] [Article Influence: 8.2] [Reference Citation Analysis]
Number Citing Articles
1 Winrow CJ, Renger JJ. Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br J Pharmacol 2014;171:283-93. [PMID: 23731216 DOI: 10.1111/bph.12261] [Cited by in Crossref: 86] [Cited by in F6Publishing: 88] [Article Influence: 10.8] [Reference Citation Analysis]
2 Roecker AJ, Mercer SP, Schreier JD, Cox CD, Fraley ME, Steen JT, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, Stevens J, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Stellabott J, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ. Discovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. ChemMedChem 2014;9:311-22. [PMID: 24376006 DOI: 10.1002/cmdc.201300447] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
3 Boss C. Orexin receptor antagonists--a patent review (2010 to August 2014). Expert Opin Ther Pat 2014;24:1367-81. [PMID: 25407283 DOI: 10.1517/13543776.2014.978859] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
4 Jacobson LH, Chen S, Mir S, Hoyer D. Orexin OX2 Receptor Antagonists as Sleep Aids. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 105-36. [DOI: 10.1007/7854_2016_47] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
5 Hoyer D, Jacobson LH. Orexin Receptor Antagonists. Curr Sleep Medicine Rep 2017;3:342-53. [DOI: 10.1007/s40675-017-0099-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Jacobson LH, Hoyer D, de Lecea L. Hypocretins (orexins): The ultimate translational neuropeptides. J Intern Med 2022. [PMID: 35043499 DOI: 10.1111/joim.13406] [Reference Citation Analysis]
7 Dale NC, Hoyer D, Jacobson LH, Pfleger KDG, Johnstone EKM. Orexin Signaling: A Complex, Multifaceted Process. Front Cell Neurosci 2022;16:812359. [DOI: 10.3389/fncel.2022.812359] [Reference Citation Analysis]
8 Connor KM, Mahoney E, Jackson S, Hutzelmann J, Zhao X, Jia N, Snyder E, Snavely D, Michelson D, Roth T, Herring WJ. A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia. Int J Neuropsychopharmacol 2016;19:pyw022. [PMID: 26979830 DOI: 10.1093/ijnp/pyw022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
9 Uslaner JM, Tye SJ, Eddins DM, Wang X, Fox SV, Savitz AT, Binns J, Cannon CE, Garson SL, Yao L, Hodgson R, Stevens J, Bowlby MR, Tannenbaum PL, Brunner J, Mcdonald TP, Gotter AL, Kuduk SD, Coleman PJ, Winrow CJ, Renger JJ. Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition. Sci Transl Med 2013;5:179ra44. [PMID: 23552372 DOI: 10.1126/scitranslmed.3005213] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 7.3] [Reference Citation Analysis]
10 Stump CA, Cooke AJ, Bruno J, Cabalu TD, Gotter AL, Harell CM, Kuduk SD, Mcdonald TP, O’brien J, Renger JJ, Williams PD, Winrow CJ, Coleman PJ. Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology. Bioorganic & Medicinal Chemistry Letters 2016;26:5809-14. [DOI: 10.1016/j.bmcl.2016.10.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
11 Chung JYL, Marcune B, Strotman HR, Petrova RI, Moore JC, Dormer PG. Synthesis of ((3 R ,6 R )-6-Methylpiperidin-3-yl)methanol via Biocatalytic Transamination and Crystallization-Induced Dynamic Resolution. Org Process Res Dev 2015;19:1418-23. [DOI: 10.1021/acs.oprd.5b00259] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
12 Cernak T, Dykstra KD, Tyagarajan S, Vachal P, Krska SW. The medicinal chemist's toolbox for late stage functionalization of drug-like molecules. Chem Soc Rev 2016;45:546-76. [DOI: 10.1039/c5cs00628g] [Cited by in Crossref: 753] [Cited by in F6Publishing: 167] [Article Influence: 125.5] [Reference Citation Analysis]
13 Boss C, Roch-brisbare C, Steiner MA, Treiber A, Dietrich H, Jenck F, von Raumer M, Sifferlen T, Brotschi C, Heidmann B, Williams JT, Aissaoui H, Siegrist R, Gatfield J. Structure-Activity Relationship, Biological, and Pharmacological Characterization of the Proline Sulfonamide ACT-462206: a Potent, Brain-Penetrant Dual Orexin 1/Orexin 2 Receptor Antagonist. ChemMedChem 2014;9:2486-96. [DOI: 10.1002/cmdc.201402258] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
14 Tsukamoto Y, Itoh S, Kobayashi M, Obora Y. Iridium-Catalyzed α-Methylation of α-Aryl Esters Using Methanol as the C1 Source. Org Lett 2019;21:3299-303. [DOI: 10.1021/acs.orglett.9b01025] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
15 Yu RP, Hesk D, Rivera N, Pelczer I, Chirik PJ. Iron-catalysed tritiation of pharmaceuticals. Nature 2016;529:195-9. [PMID: 26762456 DOI: 10.1038/nature16464] [Cited by in Crossref: 207] [Cited by in F6Publishing: 152] [Article Influence: 34.5] [Reference Citation Analysis]
16 Jacobson LH, Callander GE, Hoyer D. Suvorexant for the treatment of insomnia. Expert Rev Clin Pharmacol 2014;7:711-30. [PMID: 25318834 DOI: 10.1586/17512433.2014.966813] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
17 Morairty SR, Revel FG, Malherbe P, Moreau JL, Valladao D, Wettstein JG, Kilduff TS, Borroni E. Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS One 2012;7:e39131. [PMID: 22768296 DOI: 10.1371/journal.pone.0039131] [Cited by in Crossref: 79] [Cited by in F6Publishing: 89] [Article Influence: 7.9] [Reference Citation Analysis]
18 Hoyer D, Allen A, Jacobson LH. Hypnotics with novel modes of action. Br J Clin Pharmacol 2020;86:244-9. [PMID: 31756268 DOI: 10.1111/bcp.14180] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
19 Das S, Bobbink FD, Bulut S, Soudani M, Dyson PJ. Thiazolium carbene catalysts for the fixation of CO2 onto amines. Chem Commun (Camb) 2016;52:2497-500. [PMID: 26739571 DOI: 10.1039/c5cc08741d] [Cited by in Crossref: 104] [Cited by in F6Publishing: 4] [Article Influence: 17.3] [Reference Citation Analysis]
20 Weis E, Hayes MA, Johansson MJ, Martín-Matute B. Iridium-catalyzed C-H methylation and d 3-methylation of benzoic acids with application to late-stage functionalizations. iScience 2021;24:102467. [PMID: 34027322 DOI: 10.1016/j.isci.2021.102467] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
21 Das S, Bobbink FD, Laurenczy G, Dyson PJ. Metal-free catalyst for the chemoselective methylation of amines using carbon dioxide as a carbon source. Angew Chem Int Ed Engl 2014;53:12876-9. [PMID: 25256038 DOI: 10.1002/anie.201407689] [Cited by in Crossref: 161] [Cited by in F6Publishing: 133] [Article Influence: 20.1] [Reference Citation Analysis]
22 Sullivan S. Update on emerging drugs for insomnia. Expert Opinion on Emerging Drugs 2012;17:295-8. [DOI: 10.1517/14728214.2012.693158] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
23 McGaughey G, Bayly CI, Cox CD, Schreier JD, Breslin MJ, Bogusky M, Pitzenberger S, Ball R, Coleman PJ. Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs. J Comput Aided Mol Des 2014;28:5-12. [PMID: 24488306 DOI: 10.1007/s10822-014-9710-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
24 Connor KM, Ceesay P, Hutzelmann J, Snavely D, Krystal AD, Trivedi MH, Thase M, Lines C, Herring WJ, Michelson D. Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder. Int J Neuropsychopharmacol 2017;20:613-8. [PMID: 28582570 DOI: 10.1093/ijnp/pyx033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
25 Blundell CD, Nowak T, Watson MJ. Measurement, Interpretation and Use of Free Ligand Solution Conformations in Drug Discovery. Elsevier; 2016. pp. 45-147. [DOI: 10.1016/bs.pmch.2015.10.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
26 Habgood M. Conformational ensemble comparison for small molecules in drug discovery. J Comput Aided Mol Des 2018;32:841-52. [PMID: 29987709 DOI: 10.1007/s10822-018-0132-z] [Reference Citation Analysis]
27 Kumar A, Chanana P, Choudhary S. Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs. Pharmacological Reports 2016;68:231-42. [DOI: 10.1016/j.pharep.2015.09.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
28 Schönherr H, Cernak T. Ausgeprägte Methyleffekte in der Wirkstoff-Forschung und der Bedarf an neuen C-H-Methylierungsreaktionen. Angew Chem 2013;125:12480-92. [DOI: 10.1002/ange.201303207] [Cited by in Crossref: 120] [Cited by in F6Publishing: 91] [Article Influence: 13.3] [Reference Citation Analysis]
29 Vasilopoulos A, Krska SW, Stahl SS. C(sp3)-H methylation enabled by peroxide photosensitization and Ni-mediated radical coupling. Science 2021;372:398-403. [PMID: 33888639 DOI: 10.1126/science.abh2623] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 13.0] [Reference Citation Analysis]
30 Chabi A, Zhang Y, Jackson S, Cady R, Lines C, Herring WJ, Connor KM, Michelson D. Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. Cephalalgia 2015;35:379-88. [PMID: 25106663 DOI: 10.1177/0333102414544979] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 6.8] [Reference Citation Analysis]
31 Betschart C, Hintermann S, Behnke D, Cotesta S, Fendt M, Gee CE, Jacobson LH, Laue G, Ofner S, Chaudhari V, Badiger S, Pandit C, Wagner J, Hoyer D. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia. J Med Chem 2013;56:7590-607. [PMID: 23964859 DOI: 10.1021/jm4007627] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 6.9] [Reference Citation Analysis]
32 Gotter AL, Winrow CJ, Brunner J, Garson SL, Fox SV, Binns J, Harrell CM, Cui D, Yee KL, Stiteler M, Stevens J, Savitz A, Tannenbaum PL, Tye SJ, McDonald T, Yao L, Kuduk SD, Uslaner J, Coleman PJ, Renger JJ. The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. BMC Neurosci 2013;14:90. [PMID: 23981345 DOI: 10.1186/1471-2202-14-90] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 5.6] [Reference Citation Analysis]
33 Kuduk SD, Winrow CJ, Coleman PJ. Orexin Receptor Antagonists in Development for Insomnia and CNS Disorders. Elsevier; 2013. pp. 73-87. [DOI: 10.1016/b978-0-12-417150-3.00006-5] [Cited by in Crossref: 9] [Article Influence: 1.0] [Reference Citation Analysis]
34 Fukase Y, Sato A, Tomata Y, Ochida A, Kono M, Yonemori K, Koga K, Okui T, Yamasaki M, Fujitani Y, Nakagawa H, Koyama R, Nakayama M, Skene R, Sang BC, Hoffman I, Shirai J, Yamamoto S. Identification of novel quinazolinedione derivatives as RORγt inverse agonist. Bioorg Med Chem 2018;26:721-36. [PMID: 29342416 DOI: 10.1016/j.bmc.2017.12.039] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
35 Boss C, Roch C. Orexin research: patent news from 2016. Expert Opinion on Therapeutic Patents 2017;27:1123-33. [DOI: 10.1080/13543776.2017.1344221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
36 Lv W, Wen S, Liu J, Cheng G. Palladium-Catalyzed ortho -C–H Methylation of Benzoic Acids. J Org Chem 2019;84:9786-91. [DOI: 10.1021/acs.joc.9b01204] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
37 Yang H, Zarate C, Palmer WN, Rivera N, Hesk D, Chirik PJ. Site-Selective Nickel-Catalyzed Hydrogen Isotope Exchange in N -Heterocycles and Its Application to the Tritiation of Pharmaceuticals. ACS Catal 2018;8:10210-8. [DOI: 10.1021/acscatal.8b03717] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
38 Boss C, Roch C. Recent trends in orexin research—2010 to 2015. Bioorganic & Medicinal Chemistry Letters 2015;25:2875-87. [DOI: 10.1016/j.bmcl.2015.05.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
39 Yoshida Y, Naoe Y, Terauchi T, Ozaki F, Doko T, Takemura A, Tanaka T, Sorimachi K, Beuckmann CT, Suzuki M, Ueno T, Ozaki S, Yonaga M. Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist. J Med Chem 2015;58:4648-64. [PMID: 25953512 DOI: 10.1021/acs.jmedchem.5b00217] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 6.1] [Reference Citation Analysis]
40 Mcdonald T, Liang HA, Sanoja R, Gotter AL, Kuduk SD, Coleman PJ, Smith KM, Winrow CJ, Renger JJ. Pharmacological evaluation of orexin receptor antagonists in preclinical animal models of pain. Journal of Neurogenetics 2016;30:32-41. [DOI: 10.3109/01677063.2016.1171862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
41 Kuduk SD, Skudlarek JW, DiMarco CN, Bruno JG, Pausch MH, O'Brien JA, Cabalu TD, Stevens J, Brunner J, Tannenbaum PL, Garson SL, Savitz AT, Harrell CM, Gotter AL, Winrow CJ, Renger JJ, Coleman PJ. Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties. Bioorg Med Chem Lett 2015;25:2488-92. [PMID: 25981685 DOI: 10.1016/j.bmcl.2015.04.066] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
42 Thuy-Boun PS, Villa G, Dang D, Richardson P, Su S, Yu JQ. Ligand-accelerated ortho-C-H alkylation of arylcarboxylic acids using alkyl boron reagents. J Am Chem Soc 2013;135:17508-13. [PMID: 24124892 DOI: 10.1021/ja409014v] [Cited by in Crossref: 133] [Cited by in F6Publishing: 99] [Article Influence: 14.8] [Reference Citation Analysis]
43 Khoo SY, Brown RM. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA? CNS Drugs 2014;28:713-30. [PMID: 24942635 DOI: 10.1007/s40263-014-0179-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
44 Das S, Bobbink FD, Laurenczy G, Dyson PJ. Metal-Free Catalyst for the Chemoselective Methylation of Amines Using Carbon Dioxide as a Carbon Source. Angew Chem 2014;126:13090-3. [DOI: 10.1002/ange.201407689] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
45 Heidmann B, Gatfield J, Roch C, Treiber A, Tortoioli S, Brotschi C, Williams JT, Bolli MH, Abele S, Sifferlen T, Jenck F, Boss C. Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping Approach. ChemMedChem 2016;11:2132-46. [DOI: 10.1002/cmdc.201600175] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
46 Steverlynck J, Sitdikov R, Rueping M. The Deuterated "Magic Methyl" Group: A Guide to Site-Selective Trideuteromethyl Incorporation and Labeling by Using CD3 Reagents. Chemistry 2021;27:11751-72. [PMID: 34076925 DOI: 10.1002/chem.202101179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Kuduk SD, Skudlarek JW, Di Marco CN, Bruno JG, Pausch MA, O’brien JA, Cabalu TD, Stevens J, Brunner J, Tannenbaum PL, Gotter AL, Winrow CJ, Renger JJ, Coleman PJ. Synthesis and evaluation of carbon-linked analogs of dual orexin receptor antagonist filorexant. Bioorganic & Medicinal Chemistry Letters 2014;24:1784-9. [DOI: 10.1016/j.bmcl.2014.02.026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
48 Sato A, Fukase Y, Kono M, Ochida A, Oda T, Sasaki Y, Ishii N, Tomata Y, Fukumoto S, Imai YN, Uga K, Shibata A, Yamasaki M, Nakagawa H, Shirasaki M, Skene R, Hoffman I, Sang B, Snell G, Shirai J, Yamamoto S. Design and Synthesis of Conformationally Constrained RORγt Inverse Agonists. ChemMedChem 2019;14:1917-32. [DOI: 10.1002/cmdc.201900416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
49 Boutrel B, Steiner N, Halfon O. The hypocretins and the reward function: what have we learned so far? Front Behav Neurosci 2013;7:59. [PMID: 23781178 DOI: 10.3389/fnbeh.2013.00059] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
50 Boss C, Gatfield J, Brotschi C, Heidmann B, Sifferlen T, von Raumer M, Schmidt G, Williams JT, Treiber A, Roch C. The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders. ChemMedChem 2020;15:2286-305. [PMID: 32937014 DOI: 10.1002/cmdc.202000453] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
51 Schönherr H, Cernak T. Profound Methyl Effects in Drug Discovery and a Call for New CH Methylation Reactions. Angew Chem Int Ed 2013;52:12256-67. [DOI: 10.1002/anie.201303207] [Cited by in Crossref: 459] [Cited by in F6Publishing: 372] [Article Influence: 51.0] [Reference Citation Analysis]
52 Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ. International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology. Pharmacol Rev 2012;64:389-420. [DOI: 10.1124/pr.111.005546] [Cited by in Crossref: 114] [Cited by in F6Publishing: 107] [Article Influence: 11.4] [Reference Citation Analysis]
53 Raheem IT, Breslin MJ, Bruno J, Cabalu TD, Cooke A, Cox CD, Cui D, Garson S, Gotter AL, Fox SV, Harrell CM, Kuduk SD, Lemaire W, Prueksaritanont T, Renger JJ, Stump C, Tannenbaum PL, Williams PD, Winrow CJ, Coleman PJ. Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant. Bioorganic & Medicinal Chemistry Letters 2015;25:444-50. [DOI: 10.1016/j.bmcl.2014.12.056] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
54 Li SB, Nevárez N, Giardino WJ, de Lecea L. Optical probing of orexin/hypocretin receptor antagonists. Sleep 2018;41. [PMID: 30060151 DOI: 10.1093/sleep/zsy141] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
55 Pałasz A, Lapray D, Peyron C, Rojczyk-Gołębiewska E, Skowronek R, Markowski G, Czajkowska B, Krzystanek M, Wiaderkiewicz R. Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders. Int J Neuropsychopharmacol 2014;17:157-68. [PMID: 23702225 DOI: 10.1017/S1461145713000552] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
56 Zhao H. Modulating Conformational Preferences by Allylic Strain toward Improved Physical Properties and Binding Interactions. ACS Omega. [DOI: 10.1021/acsomega.2c00510] [Reference Citation Analysis]
57 Sifferlen T, Boller A, Chardonneau A, Cottreel E, Gatfield J, Treiber A, Roch C, Jenck F, Aissaoui H, Williams JT, Brotschi C, Heidmann B, Siegrist R, Boss C. Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2. Bioorganic & Medicinal Chemistry Letters 2015;25:1884-91. [DOI: 10.1016/j.bmcl.2015.03.035] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
58 Shariq AS, Rosenblat JD, Alageel A, Mansur RB, Rong C, Ho RC, Ragguett R, Pan Z, Brietzke E, Mcintyre RS. Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2019;92:1-7. [DOI: 10.1016/j.pnpbp.2018.12.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
59 Hökfelt T, Barde S, Xu ZD, Kuteeva E, Rüegg J, Le Maitre E, Risling M, Kehr J, Ihnatko R, Theodorsson E, Palkovits M, Deakin W, Bagdy G, Juhasz G, Prud'homme HJ, Mechawar N, Diaz-Heijtz R, Ögren SO. Neuropeptide and Small Transmitter Coexistence: Fundamental Studies and Relevance to Mental Illness. Front Neural Circuits 2018;12:106. [PMID: 30627087 DOI: 10.3389/fncir.2018.00106] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 10.8] [Reference Citation Analysis]
60 Roecker AJ, Reger TS, Mattern MC, Mercer SP, Bergman JM, Schreier JD, Cube RV, Cox CD, Li D, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, Stevens J, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Stellabott J, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett 2014;24:4884-90. [PMID: 25248679 DOI: 10.1016/j.bmcl.2014.08.041] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
61 Tannenbaum PL, Stevens J, Binns J, Savitz AT, Garson SL, Fox SV, Coleman P, Kuduk SD, Gotter AL, Marino M, Tye SJ, Uslaner JM, Winrow CJ, Renger JJ. Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs. Front Behav Neurosci 2014;8:182. [PMID: 24904334 DOI: 10.3389/fnbeh.2014.00182] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
62 Lionetto L, Negro A, Palmisani S, Gentile G, Fiore MRD, Mercieri M, Simmaco M, Smith T, Al-kaisy A, Arcioni R, Martelletti P. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opinion on Emerging Drugs 2012;17:393-406. [DOI: 10.1517/14728214.2012.709846] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
63 Zheng Y, Tice CM, Singh SB. Conformational control in structure-based drug design. Bioorganic & Medicinal Chemistry Letters 2017;27:2825-37. [DOI: 10.1016/j.bmcl.2017.04.079] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
64 Chen Q, de Lecea L, Hu Z, Gao D. The hypocretin/orexin system: an increasingly important role in neuropsychiatry. Med Res Rev 2015;35:152-97. [PMID: 25044006 DOI: 10.1002/med.21326] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
65 Fox SV, Gotter AL, Tye SJ, Garson SL, Savitz AT, Uslaner JM, Brunner JI, Tannenbaum PL, McDonald TP, Hodgson R, Yao L, Bowlby MR, Kuduk SD, Coleman PJ, Hargreaves R, Winrow CJ, Renger JJ. Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats. Neuropsychopharmacology 2013;38:2401-8. [PMID: 23722242 DOI: 10.1038/npp.2013.139] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
66 Sun S, Fu J. Methyl-containing pharmaceuticals: Methylation in drug design. Bioorganic & Medicinal Chemistry Letters 2018;28:3283-9. [DOI: 10.1016/j.bmcl.2018.09.016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 7.8] [Reference Citation Analysis]
67 Christopher JA, Aves SJ, Brown J, Errey JC, Klair SS, Langmead CJ, Mace OJ, Mould R, Patel JC, Tehan BG, Zhukov A, Marshall FH, Congreve M. Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties. Med Chem Commun 2015;6:947-55. [DOI: 10.1039/c5md00027k] [Cited by in Crossref: 11] [Article Influence: 1.6] [Reference Citation Analysis]
68 Hoyer D, Jacobson LH. Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand? Neuropeptides 2013;47:477-88. [DOI: 10.1016/j.npep.2013.10.009] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 7.4] [Reference Citation Analysis]
69 Vanda D, Zajdel P, Soural M. Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases. European Journal of Medicinal Chemistry 2019;181:111569. [DOI: 10.1016/j.ejmech.2019.111569] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
70 Roecker AJ, Cox CD, Coleman PJ. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. J Med Chem 2016;59:504-30. [PMID: 26317591 DOI: 10.1021/acs.jmedchem.5b00832] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 8.9] [Reference Citation Analysis]
71 Girardin M, Ouellet SG, Gauvreau D, Moore JC, Hughes G, Devine PN, O’shea PD, Campeau L. Convergent Kilogram-Scale Synthesis of Dual Orexin Receptor Antagonist. Org Process Res Dev 2013;17:61-8. [DOI: 10.1021/op3002678] [Cited by in Crossref: 50] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
72 Roecker AJ, Mercer SP, Harrell CM, Garson SL, Fox SV, Gotter AL, Prueksaritanont T, Cabalu TD, Cui D, Lemaire W, Winrow CJ, Renger JJ, Coleman PJ. Discovery of dual orexin receptor antagonists with rat sleep efficacy enabled by expansion of the acetonitrile-assisted/diphosgene-mediated 2,4-dichloropyrimidine synthesis. Bioorganic & Medicinal Chemistry Letters 2014;24:2079-85. [DOI: 10.1016/j.bmcl.2014.03.052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
73 Lebold TP, Bonaventure P, Shireman BT. Selective orexin receptor antagonists. Bioorg Med Chem Lett 2013;23:4761-9. [PMID: 23891187 DOI: 10.1016/j.bmcl.2013.06.057] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
74 Skudlarek JW, Dimarco CN, Babaoglu K, Roecker AJ, Bruno JG, Pausch MA, O'brien JA, Cabalu TD, Stevens J, Brunner J, Tannenbaum PL, Wuelfing WP, Garson SL, Fox SV, Savitz AT, Harrell CM, Gotter AL, Winrow CJ, Renger JJ, Kuduk SD, Coleman PJ. Investigation of orexin-2 selective receptor antagonists: Structural modifications resulting in dual orexin receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2017;27:1364-70. [DOI: 10.1016/j.bmcl.2017.02.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
75 Feng K. The quest for magic: recent advances in C(sp 3 )–H methylation. Pure and Applied Chemistry 2022;0. [DOI: 10.1515/pac-2021-1203] [Reference Citation Analysis]
76 Rappas M, Ali AAE, Bennett KA, Brown JD, Bucknell SJ, Congreve M, Cooke RM, Cseke G, de Graaf C, Doré AS, Errey JC, Jazayeri A, Marshall FH, Mason JS, Mould R, Patel JC, Tehan BG, Weir M, Christopher JA. Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis. J Med Chem 2020;63:1528-43. [PMID: 31860301 DOI: 10.1021/acs.jmedchem.9b01787] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
77 Joseph Herring W, Ge JY, Jackson S, Assaid C, Connor KM, Michelson D. Orexin Receptor Antagonism in Painful Diabetic Neuropathy: A Phase 2 Trial With Filorexant. Clin J Pain 2018;34:37-43. [PMID: 28448426 DOI: 10.1097/AJP.0000000000000503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Udvarhelyi A, Rodde S, Wilcken R. ReSCoSS: a flexible quantum chemistry workflow identifying relevant solution conformers of drug-like molecules. J Comput Aided Mol Des 2021;35:399-415. [PMID: 32803515 DOI: 10.1007/s10822-020-00337-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
79 Callander GE, Olorunda M, Monna D, Schuepbach E, Langenegger D, Betschart C, Hintermann S, Behnke D, Cotesta S, Fendt M, Laue G, Ofner S, Briard E, Gee CE, Jacobson LH, Hoyer D. Kinetic properties of "dual" orexin receptor antagonists at OX1R and OX2R orexin receptors. Front Neurosci 2013;7:230. [PMID: 24376396 DOI: 10.3389/fnins.2013.00230] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
80 Sherer EC, Lee CH, Shpungin J, Cuff JF, Da C, Ball R, Bach R, Crespo A, Gong X, Welch CJ. Systematic approach to conformational sampling for assigning absolute configuration using vibrational circular dichroism. J Med Chem 2014;57:477-94. [PMID: 24383452 DOI: 10.1021/jm401600u] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
81 Chung JYL, Zhong Y, Maloney KM, Reamer RA, Moore JC, Strotman H, Kalinin A, Feng R, Strotman NA, Xiang B, Yasuda N. Unusual Pyrimidine Participation: Efficient Stereoselective Synthesis of Potent Dual Orexin Receptor Antagonist MK-6096. Org Lett 2014;16:5890-3. [DOI: 10.1021/ol5028249] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
82 Diaz DB, Appavoo SD, Bogdanchikova AF, Lebedev Y, McTiernan TJ, Dos Passos Gomes G, Yudin AK. Illuminating the dark conformational space of macrocycles using dominant rotors. Nat Chem 2021;13:218-25. [PMID: 33589789 DOI: 10.1038/s41557-020-00620-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
83 Williams JT, Gatfield J, Roch C, Treiber A, Jenck F, Bolli MH, Brotschi C, Sifferlen T, Heidmann B, Boss C. Discovery and optimisation of 1-acyl-2-benzylpyrrolidines as potent dual orexin receptor antagonists. Med Chem Commun 2015;6:1054-64. [DOI: 10.1039/c5md00074b] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
84 Morairty SR, Wilk AJ, Lincoln WU, Neylan TC, Kilduff TS. The hypocretin/orexin antagonist almorexant promotes sleep without impairment of performance in rats. Front Neurosci 2014;8:3. [PMID: 24550767 DOI: 10.3389/fnins.2014.00003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
85 Song D, Chen L, Li Y, Liu T, Yi X, Liu L, Ling F, Zhong W. Ruthenium catalyzed α-methylation of sulfones with methanol as a sustainable C1 source. Org Chem Front 2021;8:120-6. [DOI: 10.1039/d0qo01171a] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Aynetdinova D, Callens MC, Hicks HB, Poh CYX, Shennan BDA, Boyd AM, Lim ZH, Leitch JA, Dixon DJ. Installing the “magic methyl” – C–H methylation in synthesis. Chem Soc Rev 2021;50:5517-63. [DOI: 10.1039/d0cs00973c] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 17.0] [Reference Citation Analysis]